Your browser doesn't support javascript.
loading
Additional results for 'Sequential design approaches for bioequivalence studies with crossover designs'.
Montague, Timothy H; Potvin, Diane; Diliberti, Charles E; Hauck, Walter W; Parr, Alan F; Schuirmann, Donald J.
  • Montague TH; GlaxoSmithKline, Inc., King of Prussia, PA, USA.
Pharm Stat ; 11(1): 8-13, 2012.
Article en En | MEDLINE | ID: mdl-21308974
ABSTRACT
In 2008, this group published a paper on approaches for two-stage crossover bioequivalence (BE) studies that allowed for the reestimation of the second-stage sample size based on the variance estimated from the first-stage results. The sequential methods considered used an assumed GMR of 0.95 as part of the method for determining power and sample size. This note adds results for an assumed GMR = 0.90. Two of the methods recommended for GMR = 0.95 in the earlier paper have some unacceptable increases in Type I error rate when the GMR is changed to 0.90. If a sponsor wants to assume 0.90 for the GMR, Method D is recommended. Copyright © 2011 John Wiley & Sons, Ltd.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proyectos de Investigación / Preparaciones Farmacéuticas / Estudios Cruzados Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Año: 2012 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proyectos de Investigación / Preparaciones Farmacéuticas / Estudios Cruzados Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Año: 2012 Tipo del documento: Article